Consequences of switching from a fixed 2:1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli

被引:18
|
作者
Leverstein-van Hall, Maurine A. [1 ,2 ,3 ]
Waar, Karola [4 ]
Muilwijk, Jan [1 ]
Stuart, James Cohen [5 ,6 ]
机构
[1] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control CIb, Bilthoven, Netherlands
[2] Bronovo Hosp, Dept Med Microbiol & Infect Control, NL-2597 AX The Hague, Netherlands
[3] Diaconessenhuis, Leiden, Netherlands
[4] Izore, Ctr Infect Dis Friesland, Leeuwarden, Netherlands
[5] Reg Publ Hlth Lab, Haarlem, Netherlands
[6] Med Ctr Alkmaar, Dept Microbiol, Alkmaar, Netherlands
关键词
clinical outcomes; surveillance; Etest; discs; broth microdilution; CLINICAL BREAKPOINT CHANGES; ANTIMICROBIAL RESISTANCE;
D O I
10.1093/jac/dkt218
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The CLSI recommends a fixed 2: 1 ratio of co-amoxiclav for broth microdilution susceptibility testing of Enterobacteriaceae, while EUCAST recommends a fixed 2 mg/L clavulanate concentration. The aims of this study were: (i) to determine the influence of a switch from CLSI to EUCAST methodology on Escherichia coli susceptibility rates; (ii) to compare susceptibility results obtained using EUCAST-compliant microdilution with those from disc diffusion and the Etest; and (iii) to evaluate the clinical outcome of patients with E. coli sepsis treated with co-amoxiclav in relation to the susceptibility results obtained using either method. Methods: Resistance rates were determined in three laboratories that switched from CLSI to EUCAST cards with the Phoenix system (Becton Dickinson) as well as in 17 laboratories that continued to use CLSI cards with the VITEK 2 system (bioMerieux). In one laboratory, isolates were simultaneously tested by both the Phoenix system and either disc diffusion (n = 471) or the Etest (n = 113). Medical and laboratory records were reviewed for E. coli sepsis patients treated with co-amoxiclav monotherapy. Results: Only laboratories that switched methodology showed an increase in resistance rates - from 19% in 2010 to 31% in 2011 (P<0.0001). All isolates that tested susceptible by microdilution were also susceptible by disc diffusion or the Etest, but of 326 isolates that tested resistant by microdilution, 43% and 59% tested susceptible by disc diffusion and the Etest, respectively. Among the 89 patients included there was a better correlation between clinical response and measured MICs using the Phoenix system than the Etest. Conclusions: EUCAST methodology resulted in higher co-amoxiclav E. coli resistance rates than CLSI methodology, but correlated better with clinical outcome. EUCAST-compliant microdilution and disc diffusion provided discrepant results.
引用
下载
收藏
页码:2636 / 2640
页数:5
相关论文
共 6 条
  • [1] Establishing the validity of different susceptibility testing methods to evaluate the in vitro activity of amoxicillin-clavulanate against Escherichia coli
    Maria, Diez-Aguilar
    Maria-Isabel, Morosini
    Maria-Carmen, Conejo
    Alvaro, Pascual
    Jorge, Calvo
    Luis, Martinez-Martinez
    Francesc, Marco
    Jordi, Vila
    Adriana, Ortega
    Jesus, Oteo
    Rafael, Canton
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2016, 84 (04) : 334 - 336
  • [2] Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different β-lactam resistance phenotypes
    Oliver, A
    Pérez-Vázquez, M
    Martínez-Ferrer, M
    Baquero, F
    De Rafael, L
    Cantón, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) : 862 - 867
  • [3] A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam
    Birgy, Andre
    Delecourt, Marine
    Geslain, Guillaume
    Desselas, Emilie
    Caseris, Marion
    Magnan, Melanie
    Mariani-Kurkdjian, Patricia
    Bidet, Philippe
    Bonacorsi, Stephane
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (07) : 1911 - 1914
  • [4] SUSCEPTIBILITY OF ESCHERICHIA-COLI ISOLATES WITH TEM-1 BETA-LACTAMASE TO COMBINATIONS OF BRL42715, TAZOBACTAM OR CLAVULANATE WITH PIPERACILLIN OR AMOXICILLIN
    LIVERMORE, DM
    SEETULSINGH, P
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (06) : 761 - 767
  • [5] Area of technical uncertainty for susceptibility testing of amoxicillin/clavulanate against Escherichia coli: analysis of automated system, Etest and disk diffusion methods compared to the broth microdilution reference
    Soares, A.
    Pestel-Caron, M.
    de Rohello, F. Leysour
    Bourgoin, G.
    Boyer, S.
    Caron, F.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (12) : 1685.e1 - 1685.e6
  • [6] Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships:: do the MIC obtained with 2:1 ratio testing accurately reflect activity against β-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy, S
    Sader, HS
    Fritsche, TR
    Jones, RN
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 53 (03) : 225 - 231